The results revealed that the VHL-deficient ccRCC cells except for 769-P demonstrated a higher growth inhibitory response to doxorubicin than VHL-proficient ccRCC cells tested (Fig. 1c, Supplementary Fig. 1c). Here, VHL is linked to nonpapillary renal cell carcinoma.